BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

651 related articles for article (PubMed ID: 18567516)

  • 21. Opioid-induced respiratory effects: new data on buprenorphine.
    Dahan A
    Palliat Med; 2006; 20 Suppl 1():s3-8. PubMed ID: 16764215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparable analgesic efficacy of transdermal buprenorphine in patients over and under 65 years of age.
    Likar R; Vadlau EM; Breschan C; Kager I; Korak-Leiter M; Ziervogel G
    Clin J Pain; 2008; 24(6):536-43. PubMed ID: 18574363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain.
    Davis MP
    J Support Oncol; 2012; 10(6):209-19. PubMed ID: 22809652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study.
    Steiner DJ; Sitar S; Wen W; Sawyerr G; Munera C; Ripa SR; Landau C
    J Pain Symptom Manage; 2011 Dec; 42(6):903-17. PubMed ID: 21945130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain.
    Mitra F; Chowdhury S; Shelley M; Williams G
    Pain Med; 2013 Jan; 14(1):75-83. PubMed ID: 23320402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Introduction of low dose transdermal buprenorphine -- did it influence use of potentially addictive drugs in chronic non-malignant pain patients?
    Skurtveit S; Furu K; Kaasa S; Borchgrevink PC
    Eur J Pain; 2009 Oct; 13(9):949-53. PubMed ID: 19095476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine.
    Mercadante S; Porzio G; Fulfaro F; Aielli F; Verna L; Ficorella C; Casuccio A; Riina S; Intravaia G; Mangione S
    J Pain Symptom Manage; 2007 Nov; 34(5):532-8. PubMed ID: 17629666
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Buprenorphine and the transdermal system: the ideal match in pain management.
    Budd K
    Int J Clin Pract Suppl; 2003 Feb; (133):9-14; discussion 23-4. PubMed ID: 12665118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain.
    Poulain P; Denier W; Douma J; Hoerauf K; Samija M; Sopata M; Wolfram G
    J Pain Symptom Manage; 2008 Aug; 36(2):117-25. PubMed ID: 18411010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients.
    Freye E; Anderson-Hillemacher A; Ritzdorf I; Levy JV
    Pain Pract; 2007 Jun; 7(2):123-9. PubMed ID: 17559481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.
    Sittl R; Nuijten M; Nautrup BP
    Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Buprenorphine TDS: the clinical development rationale and results.
    Radbruch L; Vielvoye-Kerkmeer A
    Int J Clin Pract Suppl; 2003 Feb; (133):15-8; discussion 23-4. PubMed ID: 12665119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of intravenous patient-controlled analgesia with buprenorphine and morphine alone and in combination during the first 12 postoperative hours: a randomized, double-blind, four-arm trial in adults undergoing abdominal surgery.
    Oifa S; Sydoruk T; White I; Ekstein MP; Marouani N; Chazan S; Skornick Y; Weinbroum AA
    Clin Ther; 2009 Mar; 31(3):527-41. PubMed ID: 19393843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
    Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
    Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Buprenorphine transdermal patch (Norspan tape)].
    Hamaguchi S; Ikeda T
    Masui; 2013 Jul; 62(7):799-807. PubMed ID: 23905402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Buprenorphine TDS: use in daily practice, benefits for patients.
    Radbruch L
    Int J Clin Pract Suppl; 2003 Feb; (133):19-22; discussion 23-4. PubMed ID: 12665120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine.
    Koltzenburg M; Pokorny R; Gasser UE; Richarz U
    Pain; 2006 Dec; 126(1-3):165-74. PubMed ID: 16901645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transdermal opioids for cancer pain.
    Cachia E; Ahmedzai SH
    Curr Opin Support Palliat Care; 2011 Mar; 5(1):15-9. PubMed ID: 21325999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of transdermal buprenorphine in the management of children with cancer-related pain.
    Ruggiero A; Coccia P; Arena R; Maurizi P; Battista A; Ridola V; Attinà G; Riccardi R
    Pediatr Blood Cancer; 2013 Mar; 60(3):433-7. PubMed ID: 23034996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Feasibility to treat pediatric cancer pain with analgesics for adults and their efficacy].
    Zhen ZJ; Sun XF; Xia Y; Ling JY; Zheng L; Luo WB; Lin H
    Ai Zheng; 2007 Aug; 26(8):866-9. PubMed ID: 17697549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.